Transforming blood vessel cells into blood stem cells
Official title: Reprogramming Gene Regulatory Networks to a Hematopoietic Stem Cell State
Funded at University of Illinois at Chicago · NIH-10863810 · Data updated 2026-11-12
This study is exploring a way to turn cells that line our blood vessels into blood-making stem cells, which could help us learn more about producing blood cells and finding new treatments for blood-related illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $511,437 |
| NIH project number | 5R01HL170286-02 |
| Project ID | NIH-10863810 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with blood disorders or those requiring hematopoietic stem cell transplantation.
✕Less likely to help
Patients with conditions unrelated to blood cell production or those who do not require stem cell therapies may not benefit from this research.
What this research studies
This research investigates how to convert endothelial cells, which line blood vessels, into hematopoietic stem cells (HSCs) that can produce blood cells. By using specific reprogramming factors, the study aims to understand the genetic changes that enable this transformation. The approach involves advanced techniques like single-cell profiling to analyze the molecular mechanisms at play during the reprogramming process. This could provide new insights into blood cell production and potential therapies for blood-related diseases.
Why it matters
Potential benefit: If successful, this research could lead to new methods for generating blood stem cells, improving treatment options for patients needing blood cell transplants.
How similar studies have gone: Other research has shown promise in reprogramming cells for therapeutic purposes, indicating that this approach could be viable.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Chronis, Konstantinos — University of Illinois at Chicago
- Study coordinator: Chronis, Konstantinos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.